19 September 2021 - Late treatment study
A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients
et al., Phytotherapy Research, doi:10.1002/ptr.7294 (Peer Reviewed)
Small RCT with 40 low risk patients in Iran, 20 treated with nano-curcumin, showing no significant difference in outcomes with treatment. Authors note that treatment can improve peripheral blood inflammatory indices and modulate immune response by decreasing Th1 and Th17 responses, increasing T regulatory responses, further reducing IL-17 and IFN-γ, and increasing suppressive cytokines TGF-β and IL-4.
|
relative improvement in SpO2, 45.7% worse, RR 1.46, p = 0.90, treatment 20, control 20.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Hassaniazad et al., 9/19/2021, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, Middle East, peer-reviewed, 12 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.